| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 24.542 | 95.738 | 201.809 | 154.552 | 306.207 | 157.354 | 306.386 | 547.250 | 627.362 | 638.219 |
| Total Income - EUR | 24.557 | 98.369 | 203.332 | 162.369 | 306.257 | 157.370 | 307.593 | 550.436 | 631.598 | 639.117 |
| Total Expenses - EUR | 17.202 | 68.780 | 160.431 | 147.094 | 255.244 | 121.423 | 239.023 | 456.594 | 500.724 | 579.827 |
| Gross Profit/Loss - EUR | 7.355 | 29.588 | 42.901 | 15.274 | 51.013 | 35.948 | 68.570 | 93.842 | 130.874 | 59.290 |
| Net Profit/Loss - EUR | 6.618 | 27.192 | 40.877 | 13.648 | 47.951 | 33.621 | 65.498 | 89.007 | 121.710 | 50.772 |
| Employees | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
Check the financial reports for the company - Reactosib S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 675 | 1.502 | 11.505 | 13.809 | 9.453 | 10.800 | 7.634 | 27.625 | 22.033 | 292.677 |
| Current Assets | 10.816 | 31.141 | 46.991 | 42.294 | 64.984 | 40.593 | 165.747 | 178.517 | 251.244 | 161.624 |
| Inventories | 9 | 1.594 | 4.396 | 19.158 | 16.081 | 17.417 | 41.070 | 54.728 | 98.464 | 92.519 |
| Receivables | 6.738 | 17.661 | 16.913 | 17.767 | 47.441 | 22.874 | 89.526 | 118.655 | 127.937 | 69.042 |
| Cash | 4.069 | 11.886 | 25.682 | 5.369 | 1.462 | 301 | 35.150 | 5.134 | 24.843 | 63 |
| Shareholders Funds | 6.663 | 27.330 | 41.130 | 22.504 | 48.044 | 33.712 | 65.587 | 89.096 | 121.799 | 80.790 |
| Social Capital | 45 | 45 | 44 | 43 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | 4.827 | 5.313 | 17.478 | 33.852 | 26.630 | 17.846 | 107.939 | 117.046 | 151.478 | 373.511 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4755 - 4755" | |||||||||
| CAEN Financial Year |
4799
|
|||||||||
Comments - Reactosib S.r.l.